利福平胶囊(Ⅱ)对肺结核患者的治疗效果及对肝功能、痰菌转阴率的影响  

The Therapeutic Effect of Rifampicin Capsules(Ⅱ)on Pulmonary Tuberculosis Patients and Its Impact on Liver Function and Sputum Negative Conversion Rate

作　　者：马夫芹 赵伟 MA Fuqin;ZHAO Wei(Department of Infectious Diseases,Xinyi People's Hospital,Xinyi,Jiangsu Province,221400 China;Department of Anesthesiology,Xinyi People's Hospital,Xinyi,Jiangsu Province,221400 China)

机构地区：[1]新沂市人民医院传染科,江苏新沂221400 [2]新沂市人民医院麻醉科,江苏新沂221400

出　　处：《系统医学》2023年第4期177-180,共4页Systems Medicine

基　　金：江苏省老年健康科研项目(LKM2022049)。

摘　　要：目的分析利福平胶囊(Ⅱ)治疗肺结核的临床效果。方法选择2020年1月—2022年12月在新沂市人民医院治疗的72例肺结核患者,按照随机数表法分为对照组(36例,采取2HRZE/4HR方案治疗),观察组[36例,2HRZE/4HR方案中利福平胶囊改用利福平胶囊(Ⅱ)]。对比两组疗效、肝功能、痰菌转阴率、病灶吸收率、空洞闭合率、不良反应发生率。结果治疗总有效率对比,观察组高于对照组(94.44%vs 77.87%),差异有统计学意义(χ^(2)=4.181,P<0.05);治疗后,观察组肝功能指标(ALT、AST、DBil)分别为(44.02±5.03)U/L、(43.26±8.37)U/L、(32.11±5.26)μmol/L,均低于对照组的(51.46±6.12)U/L、(52.45±10.55)U/L、(42.58±6.13)μmol/L,差异有统计学意义(t=5.635、4.094、7.777,P<0.05);观察组痰菌转阴率、治疗1、2个月后病灶吸收率及空洞闭合率均较对照组更高,差异有统计学意义(P<0.05);观察组不良反应发生率为13.89%,较对照组的36.11%更低,差异有统计学意义(χ^(2)=4.741,P<0.05)。结论利福平胶囊(Ⅱ)治疗肺结核效果显著,预后良好,且不良反应少,安全性较高。Objective To analyze the clinical effect of rifampicin capsule(Ⅱ)in the treatment of pulmonary tuberculosis.Methods Seventy-two patients with pulmonary tuberculosis treated in Xinyi People's Hospital from January 2020 to December 2022 were selected and divided into a control group(36 cases treated with 2HRZE/4HR regimen)and an observation group[36 cases with rifampicin capsules changed to rifampicin capsules(Ⅱ)in 2HRZE/4HR regimen]according to the random number table method.The efficacy,liver function,sputum bacteria conversion rate,lesion absorption rate,cavity closure rate,and incidence of adverse reactions were compared between the two groups.Results The total effective rate of treatment was higher in the observation group than in the control group(94.44%vs 77.87%),the difference was statistically significan(χ^(2)=4.181,P<0.05).After treatment,the liver function indexes(ALT,AST,DBil)of the observation group were(44.02±5.03)U/L,(43.26±8.37)U/L,(32.11±5.26)μmol/L,respectively,which were lower than those of the control group(51.46±6.12)U/L,(52.45±10.55)U/L,(42.58±6.13)μmol/L in the control group,the difference was statistically significant(t=5.635,4.094,7.777,P<0.05).The sputum bacteria conversion rate,lesion absorption rate and cavity closure rate After 1 or 2 months of treatment were higher in the observation group than in the control group,the difference was statistically significant(P<0.05).The incidence of adverse reactions was 13.89%in the observation group,which was lower than that of 36.11%in the control group,the difference was statistically significant(χ^(2)=4.741,P<0.05).Conclusion Rifampicin capsule(Ⅱ)is effective in the treatment of pulmonary tuberculosis with good prognosis,and has fewer adverse reactions and higher safety.

关 键 词：利福平胶囊(Ⅱ) 肺结核 肝功能 痰菌转阴率 不良反应 

分 类 号：R575[医药卫生—消化系统]